Protein replacement therapy has tremendous promise to treat those suffering from EB. With this therapy, we believe that these children could do many things that they could not do previously.
(PRWEB) July 20, 2011
Dr. Lane is a Professor of Dermatology at Stanford University and served as the Chairman of Stanford’s Dermatology department from 1995 – 2010. Dr. Marinkovich is an Associate Professor of Dermatology, a Founding Member of the Program for Epithelial Biology and the Director of the Blistering Disease Clinic at Stanford. The JGSF grant will support Drs. Lane and Marinkovich’s protein replacement therapy, which, through a proprietary delivery method, will deliver the missing protein, type VII collagen, to the optimal location and with the optimal dose to a child suffering from EB. Replacing the missing protein in a child with Dystrophic EB would potentially enable his or her skin to act more normally, thereby changing this child’s quality of life significantly. Dr. Lane commented “The support from the JGSF allows us to work toward making this an effective therapy. It allows us to expand and develop our research in additional directions, bringing us closer to successful therapies. We are working towards completing the Food and Drug Administration requirements necessary for type VII collagen injections in patients." Added Dr. Marinkovich “Protein replacement therapy has tremendous promise to treat those suffering from EB. We believe that our approach has the ability to change the quality of life of these children. With this therapy, we believe that these children could do many things that they could not do previously.”
The Epidermolysis Bullosa Clinical Research Consortium (EBCRC) was formed to advance knowledge about EB and to improve outcomes for affected children and adults through excellence in collaborative research, education, and advocacy. The goal is to conduct collaborative clinical and translational research in EB and improve the care of patients suffering from the disease. Current members of the EBCRC are leading physicians and researchers at the Children’s Hospital (University of Colorado), Cincinnati Children’s Hospital, Columbia University, Henry Ford Hospital (Detroit), Hospital for Sick Children (Toronto), Northwestern University, Stanford University and University of Miami. Said Dr. Lane “The EBCRC is a critical initiative in building the infrastructure to support research trials and developments in the EB community."
To learn more about JGSF and to support its efforts, please visit http://www.jgsf.org
JGSF is grateful to EB Medical Research Foundation (EBMRF) for partnering in the funding of these promising research projects and to DebRA of America for providing valuable resources in evaluating this research.
About the Jackson Gabriel Silver Foundation:
The Jackson Gabriel Silver Foundation was founded with the mission to find treatments and cures for Epidermolysis Bullosa (“EB”), a group of incurable and devastating blistering disorders that affect children from birth. By funding scientific research, JGSF can help children with EB who lack the critical proteins that act like Velcro, binding their layers of skin together. JGSF has funded almost $300,000 of research since 2009.